59 related articles for article (PubMed ID: 16186542)
1. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.
van Oostrom JC; Maguire RP; Verschuuren-Bemelmans CC; Veenma-van der Duin L; Pruim J; Roos RA; Leenders KL
Neurology; 2005 Sep; 65(6):941-3. PubMed ID: 16186542
[TBL] [Abstract][Full Text] [Related]
2. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
[TBL] [Abstract][Full Text] [Related]
3. Reduced D
Weiss AR; Bertoglio D; Liguore WA; Brandon K; Templon J; Link J; McBride JL
Mov Disord; 2023 Jan; 38(1):143-147. PubMed ID: 36544385
[TBL] [Abstract][Full Text] [Related]
4. Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington's disease gene-expansion carriers: The significance of partial volume correction.
Hellem MNN; Vinther-Jensen T; Anderberg L; Budtz-Jørgensen E; Hjermind LE; Larsen VA; Nielsen JE; Law I
PLoS One; 2021; 16(6):e0252683. PubMed ID: 34115782
[TBL] [Abstract][Full Text] [Related]
5. MR Biomarkers of Degenerative Brain Disorders Derived From Diffusion Imaging.
Andica C; Kamagata K; Hatano T; Saito Y; Ogaki K; Hattori N; Aoki S
J Magn Reson Imaging; 2020 Dec; 52(6):1620-1636. PubMed ID: 31837086
[TBL] [Abstract][Full Text] [Related]
6. Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.
Fazio P; Paucar M; Svenningsson P; Varrone A
Curr Neurol Neurosci Rep; 2018 Oct; 18(12):85. PubMed ID: 30291526
[TBL] [Abstract][Full Text] [Related]
7. Multiple clinical features of Huntington's disease correlate with mutant HTT gene CAG repeat lengths and neurodegeneration.
Podvin S; Reardon HT; Yin K; Mosier C; Hook V
J Neurol; 2019 Mar; 266(3):551-564. PubMed ID: 29956026
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease.
Agosta F; Altomare D; Festari C; Orini S; Gandolfo F; Boccardi M; Arbizu J; Bouwman F; Drzezga A; Nestor P; Nobili F; Walker Z; Pagani M;
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1546-1556. PubMed ID: 29717332
[TBL] [Abstract][Full Text] [Related]
9. Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.
Morigaki R; Goto S
Brain Sci; 2017 Jun; 7(6):. PubMed ID: 28590448
[TBL] [Abstract][Full Text] [Related]
10. Molecular Imaging Markers to Track Huntington's Disease Pathology.
Wilson H; De Micco R; Niccolini F; Politis M
Front Neurol; 2017; 8():11. PubMed ID: 28194132
[TBL] [Abstract][Full Text] [Related]
11. Current status of PET imaging in Huntington's disease.
Pagano G; Niccolini F; Politis M
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1171-82. PubMed ID: 26899245
[TBL] [Abstract][Full Text] [Related]
12. PET Imaging in Huntington's Disease.
Roussakis AA; Piccini P
J Huntingtons Dis; 2015; 4(4):287-96. PubMed ID: 26683130
[TBL] [Abstract][Full Text] [Related]
13. T1ρ imaging in premanifest Huntington disease reveals changes associated with disease progression.
Wassef SN; Wemmie J; Johnson CP; Johnson H; Paulsen JS; Long JD; Magnotta VA
Mov Disord; 2015 Jul; 30(8):1107-14. PubMed ID: 25820773
[TBL] [Abstract][Full Text] [Related]
14. Neuroimaging in Huntington's disease.
Niccolini F; Politis M
World J Radiol; 2014 Jun; 6(6):301-12. PubMed ID: 24976932
[TBL] [Abstract][Full Text] [Related]
15. Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease.
Herben-Dekker M; van Oostrom JC; Roos RA; Jurgens CK; Witjes-Ané MN; Kremer HP; Leenders KL; Spikman JM
J Neurol; 2014 Jul; 261(7):1387-97. PubMed ID: 24781835
[TBL] [Abstract][Full Text] [Related]
16. Huntington disease: natural history, biomarkers and prospects for therapeutics.
Ross CA; Aylward EH; Wild EJ; Langbehn DR; Long JD; Warner JH; Scahill RI; Leavitt BR; Stout JC; Paulsen JS; Reilmann R; Unschuld PG; Wexler A; Margolis RL; Tabrizi SJ
Nat Rev Neurol; 2014 Apr; 10(4):204-16. PubMed ID: 24614516
[TBL] [Abstract][Full Text] [Related]
17. Cross sectional PET study of cerebral adenosine A₁ receptors in premanifest and manifest Huntington's disease.
Matusch A; Saft C; Elmenhorst D; Kraus PH; Gold R; Hartung HP; Bauer A
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1210-20. PubMed ID: 24566949
[TBL] [Abstract][Full Text] [Related]
18. Metabolic network as a progression biomarker of premanifest Huntington's disease.
Tang CC; Feigin A; Ma Y; Habeck C; Paulsen JS; Leenders KL; Teune LK; van Oostrom JC; Guttman M; Dhawan V; Eidelberg D
J Clin Invest; 2013 Sep; 123(9):4076-88. PubMed ID: 23985564
[TBL] [Abstract][Full Text] [Related]
19. Monitoring Huntington's disease progression through preclinical and early stages.
Tang C; Feigin A
Neurodegener Dis Manag; 2012 Aug; 2(4):421-435. PubMed ID: 23243467
[TBL] [Abstract][Full Text] [Related]
20. A novel BACHD transgenic rat exhibits characteristic neuropathological features of Huntington disease.
Yu-Taeger L; Petrasch-Parwez E; Osmand AP; Redensek A; Metzger S; Clemens LE; Park L; Howland D; Calaminus C; Gu X; Pichler B; Yang XW; Riess O; Nguyen HP
J Neurosci; 2012 Oct; 32(44):15426-38. PubMed ID: 23115180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
